Terragen Holdings Limited Overview
Terragen Holdings is a Queensland-based agricultural biotechnology company. It develops, manufactures and sells live-microbe ("probiotic") products for livestock and crops. Its commercial portfolio has four lines:
- Mylo®, a liquid ruminant feed supplement
Terragen Probiotic for Ruminants™ (TPR): and TPR Ultra, a dry-format probiotic aimed at beef and lamb feedlots
-
Great Land Plus® (GLP), a liquid plant biostimulant and soil conditioner
-
Naturalift®, a consumer home-garden probiotic launched in November 2025
The company sits at the very early, sub-scale end of the global agricultural biologicals industry. FY2026 revenue was A$1.43 million against a net loss of A$3.75 million, and the business is funded by periodic equity raisings and R&D tax refunds. Its investment case rests on converting large independent trials into recurring feedlot volume and North American market access:
-
A 10,600-head Mort & Co / MLA trial, externally funded up to A$2.8 million
-
A first commercial feedlot contract (Ravensworth)
-
A Canadian government feedlot study
-
A US regulatory filing that the company expects to be approved in December 2026
Company's own description (paraphrased from the FY2026 Annual Report)
The company describes itself as an Australian agricultural biotechnology business. It applies proprietary microbial technology to improve animal health and productivity, crop performance and soil health.
Its stated principal activities are research, development and commercialisation of biological products that enhance animal and plant health for use in agriculture. Management said FY2026 marked a shift in focus from product development and launch towards commercial validation and broader market adoption.
The Annual Report positions:
-
the animal probiotics (Mylo® and TPR) as feed supplements that lift average daily weight gain and reduce methane production, and
-
Great Land Plus® as a biostimulant that reduces reliance on chemical fertilisers while increasing yields and soil organic carbon.
Independent characterisation
Terragen is best understood as a single-technology-platform, pre-scale biologicals developer with a thin commercial revenue base. Its core competence is selecting, fermenting and formulating naturally occurring bacterial consortia. Lactobacillus and Acetobacter genera are cited in IPO-era descriptions of Great Land. It then validates them through field trials.
Commercially, the company behaves like a branded input supplier selling through Australian agri-retail channels. These include Nutrien Ag Solutions, whose national supply agreement was extended in the June 2026 quarter to cover TPR as well as GLP, plus a network of retail agency partners and online sales. It also sells directly to large feedlots.
Four features stand out:
-
Concentration. Two unnamed customers each contributed more than 10% of FY2026 revenue: Customer A with A$200,533 and Customer B with A$158,036. Together they account for about 25% of sales (FY2026 Annual Report Note 5).
-
Animal-led mix. Animal probiotics were 78.4% of FY2026 sales and plant biostimulants 21.6% (Note 3).
-
Australian dependence. Australia contributed 98.1% of FY2026 revenue (Note 5).
-
Subsidy-assisted economics. The R&D tax incentive (A$642,691 in FY2026) was equivalent to 45% of revenue and is now presented within "other income".
Revenue model
| Revenue type | Presence | Comment (source: FY2026 Annual Report, Note 3 and accounting policy) |
|---|---|---|
| Product sales | 100% of revenue | Recognised at a point in time on delivery. Sales are made directly to customers and through agri-retail. |
| Services | None disclosed | Trial programmes are funded by partners (e.g., the MLA Donor Company) but are not booked as service revenue. |
| Subscription | — | Not applicable |
| Licensing / royalties | None to date | The company states its long-term viability depends partly on entering licensing or distribution arrangements. A North American distribution agreement is targeted (expected January 2027 per the Q4 FY2026 report). |
| Other income (non-revenue) | Material | R&D tax incentive A$642,691, interest A$153,499 and freight recovery A$3,069 in FY2026 |
Value-chain position
Terragen operates across these stages:
Upstream: proprietary strain library and IP (patents across Australia, New Zealand, the US and Europe, per the FY2026 risk table)
Midstream: manufacturing at its Coolum facility under GMP standards prescribed by the APVMA. Liquid Mylo and GLP, and dry TPR, are made at commercial scale. US manufacturing partners are scaling up TPR strain production (Q4 FY2026 report).
Downstream: branding, veterinary and product-manager sales support, retailer distribution, and installation of automated microbial dispensers at feedlots (Grassdale in May 2026; Ravensworth is a condition precedent)
Customer types and end-markets
| End-market | Products | Customer type |
|---|---|---|
| Dairy (calves and cows) | Mylo® Calves / Mylo® Cows | Dairy farmers in Australia and New Zealand; NZ via distributor Nutritech International (appointed 2023) |
| Beef feedlots and grass-fed beef | TPR, TPR Ultra, Mylo® Beef | Feedlot operators (Ravensworth, Mort & Co Grassdale) |
| Lamb / sheep | Dry Mylo / TPR, Mylo® Lamb | Lamb feedlots and producers |
| Broadacre and horticulture cropping | Great Land Plus® (including a pasture variant) | Growers of maize, canola, winter cereals and horticulture (e.g., avocado trials) |
| Consumer home garden | Naturalift® | Australian households, via online channels |
| Companion animals (pipeline) | Canine probiotic | Pet owners and veterinary channel (not yet commercial) |
Strategy
Stated strategy (themes paraphrased from the FY2026 Chair and MD report)
The company's FY2027 framing is to turn scientific validation and commercial trials into sustainable revenue growth. It does this by proving performance at commercial scale and building the partnerships and distribution channels needed to reach larger markets.
Its three stated FY2027 priorities:
-
Feedlot adoption of TPR, through the Ravensworth supply agreement, the Mort & Co Grassdale trial and broader feedlot engagement.
-
International expansion, through the Canadian trials, regulatory approvals and North American commercial partnerships.
-
Revenue diversification, by growing GLP, Naturalift and companion-animal opportunities while advancing next-generation microbial technology.
The Board describes its approach as disciplined investment, commercial execution and partnership-led adoption.
Initiatives announced in the last 24 months
| Initiative | Date | Detail | Status |
|---|---|---|---|
| TPR / TPR Ultra dry-format launch | 25 Mar 2025 | Opens beef and lamb feedlot segments | Commercial; transition from Mylo is slower than planned |
| Naturalift® consumer launch | Nov 2025 | First consumer-channel product | Commercial (online) |
| A$7.0M placement | Feb–Mar 2026 | 318.2M shares at A$0.022; Ward entities subscribe A$2.25M | Completed |
| GLP maize silage validation | 3 Mar 2026 | Laconik independent assessment: +12% yield | Completed |
| Ravensworth Feedlot supply agreement | 28 May 2026 | Minimum 360,000 TPR doses plus GLP. Conditions: a Terragen-funded dispenser and Ravensworth's feedlot expansion. Order due by the later of 1 Dec 2026 or 90 days after conditions are met. 12-month term from first delivery (late CY2026). | Conditional |
| Mort & Co / MLA Donor Company trial | May 2026 – Dec 2026 | Up to 10,600 head, 20 replicated data sets, Charles Sturt University protocols, carcass evaluation at Kilcoy; externally funded up to A$2.8M. A supply agreement with Mort & Co is executed but conditional on trial success. | In progress; data expected Jan 2027 |
| Nutrien national supply agreement extension | Jun quarter 2026 | Extends to TPR alongside GLP; more than 700 locations | Executed |
| North American market access | Ongoing | Knoell as regulatory consultant; US approval expected Dec 2026; AAFC feedlot study; US manufacturing scale-up; distribution agreement targeted Jan 2027 | In progress |
| QUT / Food Agility nitrogen-efficiency microbes | Ongoing | Three formulations in greenhouse trials | R&D |
| FAR Australia / COGGO winter crop trials | 2026 season | Independent benchmarking | In progress |
| Canine probiotic | Ongoing | Safety, palatability and SCFA work done; microbiome data due Nov 2026 | Pre-commercial |
Medium-term targets and guidance
The company gives no formal revenue or earnings guidance. Its only quantified forward statement, from the Q4 FY2026 report, says the two supply agreements plus current sales could lift TPR use to 160,000 head of beef cattle in CY2027. That outcome assumes:
-
a successful Mort & Co trial and subsequent orders;
-
Ravensworth using TPR across operations of up to 40,000 head per day, then extending it across the whole feedlot; and
-
stable existing TPR sales.
The 28 May 2026 announcement also referenced a potential 25–50% sales increase in early 2027 contingent on KPIs (as summarised by InvestSMART).
ESG and cost targets: no formal emissions or cost-reduction targets have been disclosed.
Products & Services
Animal Probiotics
1. Mylo® (liquid) — Mylo® Calves, Mylo® Cows, Mylo® Beef, Mylo® Lamb
Description: a liquid microbial feed supplement containing a selected blend of live, naturally occurring microbes. It is described as antibiotic- and hormone-free and certified organic (Nov 2025 investor deck). IPO-era descriptions credit the company's "AmpliBoost" technology.
Claimed benefits: - Higher average daily weight gain and reduced methane production (FY2026 Annual Report)
-
Calf growth and health
-
Cow productivity: the Harrisville, QLD longitudinal dairy study was released in FY2023
Target customers: dairy farmers in Australia and New Zealand, plus some beef and lamb producers
Launch: on market by 2018
Pricing: not publicly disclosed
Status: customers are being transitioned to dry-format TPR. Management says this transition is taking longer than expected as customers work through existing Mylo inventory (FY2026 Annual Report).
2. Terragen Probiotic for Ruminants™ (TPR) — dry format
Description: a dry-format version of the Mylo microbial technology ("Dry Mylo") developed for feedlots. Development took more than 18 months and covered prototyping, dose-rate optimisation, formulation, stability and compatibility testing, and field trials.
Launch: 25 March 2025 (FY2026 Annual Report). The 1H FY2026 report says late April 2025.
Channels: online, leading Australian agri-retailers, and Nutrien Ag Solutions (added June quarter 2026). Feedlots are supplied direct through automated dispensers.
Evidence base: - A Charles Sturt University controlled feeding trial: about A$57 more value per carcass and up to 4.7% heavier live weight after a 100-day programme. Terragen cites an ROI of about 9x at NFAS pricing (Q4 FY2026 report).
- An earlier dry Mylo lamb weight-gain study
Commercial traction: an 87% quarter-on-quarter uplift in TPR sales was reported in a late-2025 quarterly (as cited by TradingView). The Ravensworth contract has a minimum of 360,000 doses.
3. Terragen Probiotic Ultra for Ruminants™ (TPR Ultra)
Description: a premium or higher-specification variant launched alongside TPR in March 2025, targeted at feedlots
Current use: the formulation in the 10,600-head Mort & Co / MLA trial
Pricing: not publicly disclosed
Plant Bio-stimulants
4. Great Land Plus® (GLP)
Description: a patented liquid biological soil conditioner and plant biostimulant. IPO-era descriptions cite live Lactobacillus and Acetobacter species. Claimed benefits include greater nutrient availability, root development, stress tolerance, soil organic carbon and reduced chemical fertiliser use.
Variant: a Great Land Plus Pasture® variant appears in the Nov 2025 deck
Evidence base: - Independent Laconik assessment (announced 3 March 2026): a 12% maize silage yield uplift at 4 L/ha across 13 replicated data sets, worth about A$1,100/ha extra gross revenue and an estimated ROI of up to 20x
-
Bundaberg avocado trial (pre-IPO): a 10% yield benefit
-
Applied research on maize and canola (capitalised development costs, FY2026 Note 11)
Customers: broadacre and horticultural growers, Ravensworth (bundled with TPR), and Mort & Co Fertilisers (purchase order 4 February 2026)
FY2026 revenue (category): A$308,876, up 16.2%
5. Naturalift® (consumer garden probiotic)
Launch: November 2025, through dedicated online channels with nationwide distribution
Description: an organic plant probiotic range for lawns, gardens, indoor plants and home horticulture, using the GLP microbial technology
Revenue contribution: not separately disclosed (included within plant bio-stimulants)
Pipeline (not yet commercial)
| Programme | Description | Status (latest source) |
|---|---|---|
| Canine probiotic (Terragen Probiotic® Companion Animal) | First companion-animal product | Invetus safety and palatability trial completed. Faecal short-chain fatty acid analysis showed positive shifts. Microbiome sequencing results were due in November 2026. Manufacturing and distribution partner discussions are ongoing. (Q4 FY2026 report) |
| Nitrogen-use-efficiency microbes ("Microbial Solutions for Agricultural Emissions") | Strains that improve nitrogen use efficiency and promote plant growth; collaboration with QUT and Food Agility CRC | Three formulations selected for greenhouse trials, with small-scale field work to follow (Q4 FY2026 report) |
| Winter-crop biologicals | Benchmarking GLP and new biologicals in cereals and canola | FAR Australia Biological Benchmarking Program and COGGO (WA) showcase trials under way (Q4 FY2026 report) |
| North American TPR | US and Canadian market access; US contract manufacturing | Knoell expects US approval in December 2026. The AAFC feedlot study concludes in December 2026, with data expected in January 2027. (Q4 FY2026 report) |
| Brazil TPR | Regulatory market access | Engagement in progress (FY2026 Annual Report) |
| Lactolin, Halo | Legacy IPO-era products intended for the US and Europe | No recent disclosure; current status not publicly disclosed |
Financial Narrative
Income statement
Notes on the income statement:
-
FY2022–FY2024 EBIT and pre-tax figures are from the FY2023 release and the StockAnalysis/Kalkine aggregator.
-
Before FY2026, pre-tax losses exceeded net losses because the R&D incentive was booked as a tax benefit.
-
FY2025 and FY2026 EBIT is derived: pre-tax loss plus finance costs.
-
FY2025 and FY2026 EBITDA is derived: EBIT plus depreciation and amortisation (A$0.253M and A$0.428M).
Margins and growth
Revenue CAGR, FY2022–FY2026 (four years):
-
Statutory basis (A$2.89M to A$1.43M): −16.1% per year
-
Net-sales basis for FY2022 (A$2.20M): −10.2% per year
Balance sheet
Notes on the balance sheet:
Debt composition: FY2026 debt is chattel mortgages of A$0.251M plus lease liabilities of A$0.024M. FY2025 debt is insurance premium funding of A$0.176M, chattel mortgages of A$0.394M and leases of A$0.166M.
Net cash cross-check: Aggregator net cash for FY2022 to FY2024 is A$6.47M, A$4.07M and A$4.12M, using StockAnalysis definitions.
Going concern: The going-concern note relies on cash-flow forecasts showing sufficient cash through 31 March 2028.
Cash flow
FY2022–FY2024 free cash flow is from StockAnalysis (aggregator). FY2025 capex includes A$0.605M of capitalised TPR and GLP development costs.
FY2026 operating cash detail (Appendix 4C YTD, A$'000):
-
Receipts from customers: 1,394
-
R&D payments: (667)
-
Manufacturing and operating costs: (1,261)
-
Advertising and marketing: (253)
-
Staff: (2,648)
-
Administration and corporate: (1,024)
-
R&D tax incentive received: 989
-
Net operating cash flow: (3,378)
Liquidity:
-
Q4 FY2026 operating burn was A$0.984M, which the company equates to about 7 quarters of funding.
-
The Q1 FY2027 Appendix 4C (September 2026 quarter) is due by 31 October 2026 and had not been released at the research date.
Commentary: trends, inflections and drivers
Revenue. Revenue has fallen for three consecutive years, from A$3.28M statutory in FY2023 to A$1.43M in FY2026, roughly a 56% decline. Management attributes the FY2026 decline (FY2026 Annual Report) to:
-
drought across key target markets;
-
slower-than-expected adoption;
-
a protracted channel transition from liquid Mylo to dry TPR, as customers ran down existing inventory; and
-
long evaluation cycles at large feedlots.
The FY2024 decline of 35% is consistent with a downturn in dairy-calf Mylo demand and channel destocking.
Two positive inflections stand out:
-
Plant biostimulant sales rose 16% in FY2026.
-
Gross margin recovered from 49.0% to 59.3%. Cost of sales fell 29%, partly because FY2025 carried TPR launch production costs; employee costs within cost of sales fell from A$0.49M to A$0.12M.
Cost base. Operating expenses fell 6.9% to A$5.98M. Sales and marketing fell A$0.41M after the launch year. R&D rose 11.5% to A$1.22M, driven by the canine programme. Administration was flat at A$2.82M; it remains roughly twice revenue and is the main structural problem in the P&L. Employee benefits fell 10.9%, and termination benefits dropped from A$184k to A$41k.
Losses. Net loss has been stuck at A$3.0–3.75M for four years. Gross profit is too small to absorb a fixed cost base of about A$5.5–6.0M. Other income (mostly the R&D incentive) covers roughly 13–18% of costs. Per-share losses have fallen faster than absolute losses because the share count has more than doubled: weighted shares rose from 438.4M in FY2025 to 600.1M in FY2026, and shares on issue rose from 369.1M at 30 June 2024 to 823.2M at 30 June 2026.
Balance sheet. The balance sheet is clean: no bank debt, no goodwill, and A$7.25M of cash against A$1.09M of total liabilities. The equity line has grown only through raisings. Issued capital is A$57.9M against accumulated losses of A$49.0M, so about 85% of all capital ever contributed has been consumed by losses.
Cash flow. Free cash burn has averaged about A$3.5M per year over FY2022–FY2026. FY2026 burn was inflated by an inventory build of about A$0.48M (raw materials up from A$0.37M to A$0.74M) ahead of expected Ravensworth and Mort & Co volumes.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment (AUD)
| Segment | FY2025 | FY2026 |
|---|---|---|
Australia revenue (AUD) | 1,598,617 | 1,404,261 |
New Zealand revenue (AUD) | 16,636 | 27,821 |
Total revenue (AUD) | 1,615,253 | 1,432,082 |
Revenue by Segment (AUD) — Australia segment result
| Segment | FY2025 | FY2026 |
|---|---|---|
Australia segment result (AUD) | -3,745,941 | -3,774,583 |
New Zealand segment result (AUD) | 22,111 | 23,216 |
Group result (AUD) | -3,723,830 | -3,751,367 |
Segment Revenue
| Metric | Australia | New Zealand |
|---|---|---|
Revenue YoY growth | −12.2% | +67.2% |
% of group revenue | 98.1% | 1.9% |
Segment result margin | −268.8% | +83.4% |
Segment assets (AUD) | 10,527,450 | 64,968 |
Additions to non-current assets (AUD) | 153,228 | 0 |
Revenue by Segment (AUD) by Product Category
| Product category | FY2025 | FY2026 |
|---|---|---|
Animal probiotics revenue (AUD) | 1,349,371 | 1,123,206 |
Plant bio-stimulants revenue (AUD) | 265,882 | 308,876 |
Revenue by Segment (%)
| Product category (%) | FY2026 YoY | FY2026 share |
|---|---|---|
Animal probiotics | −16.8% | 78.4% |
Plant bio-stimulants | +16.2% | 21.6% |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue, statutory (AUD Mn) | 2.89 | 3.28 | 2.14 | 1.62 | 1.43 |
Net sales net of commissions, company-reported (AUD Mn) | 2.20 | 2.47 | — | — | — |
Cost of sales (AUD Mn) | — | — | 0.77 | 0.82 | 0.58 |
Gross profit (AUD Mn) | — | — | 1.37 | 0.79 | 0.85 |
Other income incl. R&D incentive (AUD Mn) | — | — | — | 1.09 | 0.80 |
Sales and marketing expense (AUD Mn) | — | — | — | 1.73 | 1.31 |
R&D expense (AUD Mn) | — | — | — | 1.10 | 1.22 |
Admin and other expense (AUD Mn) | — | — | — | 2.75 | 2.82 |
Operating income excl. other income (AUD Mn) | — | — | — | -4.78 | -4.51 |
EBIT (AUD Mn) | -6.29 | -3.97 | -3.85 | -3.69 | -3.71 |
EBITDA (AUD Mn) | — | — | — | -3.44 | -3.29 |
Pre-tax income (AUD Mn) | -6.30 | -3.98 | -3.88 | -3.72 | -3.75 |
Net income (AUD Mn) | -5.41 | -3.23 | -3.01 | -3.72 | -3.75 |
EPS basic and diluted (A$ cents) | -2.80 | -1.57 | -0.87 | -0.85 | -0.63 |
Dividends per share (A$ cents) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue growth (%) | -19.7 | 13.2 | -35.9 | -24.4 | -11.3 |
Gross margin (%) | — | — | 64.0 | 49.0 | 59.3 |
Operating margin excl. other income (%) | — | — | — | -296.0 | -315.2 |
EBITDA margin (%) | — | — | — | -212.9 | -229.5 |
Net margin (%) | -187.2 | -98.5 | -140.7 | -230.5 | -262.0 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (AUD Mn) | — | — | — | 8.12 | 10.59 |
Cash and equivalents (AUD Mn) | 6.67 | 4.17 | 4.54 | 4.70 | 7.25 |
Trade and other receivables (AUD Mn) | — | — | — | 0.95 | 0.68 |
Inventories (AUD Mn) | — | — | — | 0.50 | 0.97 |
Intangible assets incl. patents and capitalised development (AUD Mn) | — | — | — | 0.89 | 0.76 |
Goodwill (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Short-term debt incl. leases (AUD Mn) | — | — | — | 0.42 | 0.11 |
Long-term debt incl. leases (AUD Mn) | — | — | — | 0.32 | 0.16 |
Total debt (AUD Mn) | — | — | — | 0.74 | 0.28 |
Net debt, negative = net cash (AUD Mn) | — | — | — | -3.97 | -6.98 |
Total equity (AUD Mn) | — | — | 5.32 | 6.57 | 9.50 |
Working capital (AUD Mn) | — | — | — | 5.22 | 8.30 |
Issued capital (AUD Mn) | — | — | 46.90 | 51.30 | 57.88 |
Accumulated losses (AUD Mn) | — | — | -43.27 | -46.99 | -48.99 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (AUD Mn) | — | — | — | -3.03 | -3.38 |
Capex incl. intangibles (AUD Mn) | — | — | — | 0.68 | 0.18 |
Free cash flow (AUD Mn) | -4.95 | -2.86 | -2.35 | -3.71 | -3.55 |
Equity raised, gross (AUD Mn) | — | — | — | 4.76 | 7.00 |
Capital raising costs (AUD Mn) | — | — | — | 0.36 | 0.42 |
Dividends paid (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Buybacks (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
R&D tax incentive cash received (AUD Mn) | — | — | — | 0.97 | 0.99 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2025 | FY2026 | Comment |
|---|---|---|---|
ROE (%) | -62.7 | -46.7 | Net loss divided by average equity |
ROA (%) | not computed | -40.1 | — |
Current ratio (x) | 5.34 | 10.34 | Boosted by the A$7M placement |
Debt / equity (x) | 0.11 | 0.03 | Hire purchase and leases only |
Asset turnover (x) | not computed | 0.15 | Revenue divided by average total assets |
DSO (days) | 42 | 41 | Company-stated average credit period |
DPO (days) | 32 | 31 | Company-stated |
DIO (days, year-end inventory / COGS) | 220 | 609 | Inflated by bulk microbial strain purchases ahead of the TPR ramp |
Cash conversion cycle (days) | about 230 | about 619 | Derived; distorted by the inventory build |
NTA per share (A$ cents) | 1.13 | 1.06 | FY2026 Appendix 4E |
Revenue by Region (AUD)
| Region | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Australia revenue (AUD) | — | 1,598,617 | 1,404,261 |
New Zealand revenue (AUD) | — | 16,636 | 27,821 |
Rest of world revenue (AUD) | 0 | 0 | 0 |
Total revenue (AUD) | 2,137,088 | 1,615,253 | 1,432,082 |
Per-Share Data and Share Count (millions)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|
Share price at 30 June (A$ cents) | 28.0 | 15.5 | 2.4 | 1.3 | 1.9 | 1.6 |
Shares on issue at 30 June (millions) | — | — | — | 369.1 | 505.0 | 823.2 |
Market capitalisation at 30 June (AUD Mn) | — | — | — | 4.8 | 9.6 | 13.2 |
Share Price & Returns
| Period | Return | Basis |
|---|---|---|
1 year (Oct 2025 – Oct 2026) | Not precisely verified; price range A$0.014–0.030 | Yahoo Finance 52-week range; last A$0.022 (2 Oct 2026) |
3 years (from 30 Jun 2023 close of 2.4c) | About −8% | Derived, to A$0.022 |
5 years (from 30 Jun 2021 close of 28.0c) | About −92% | Derived |
Since IPO (A$0.25 prospectus price) | About −91% | Derived; Stoxray shows −90.8% since IPO |
Valuation Multiples
| Multiple | Terragen | Peers |
|---|---|---|
P/E | Not meaningful (loss) | — |
EV / Sales | About 7.8x (EV of about A$11.1M = market cap A$18.1M − net cash A$7.0M; divided by revenue of A$1.43M) | MarketScreener shows EV/Sales of 2.92x for 2026 on an earlier, lower price and different EV basis. |
EV / EBITDA | Not meaningful (negative EBITDA) | — |
P/B | About 1.9x (A$18.1M / A$9.5M equity) | — |
P/NTA | About 2.1x (A$0.022 / 1.06c) | — |
Capital Markets
| Item | Status |
|---|---|
Analyst consensus | None. No sell-side coverage identified. |
Dividend history and policy | Never paid a dividend; no dividend reinvestment plan; franking 0% |
Buybacks | None authorised or executed |
Credit ratings (Moody's / S&P / Fitch) | Not rated |
Debt maturity profile | Chattel mortgages A$0.251M (A$0.090M current, A$0.161M non-current) and leases A$0.024M (due within 1 year). All facilities mature within 4 years and are secured against assets with a written-down value of A$0.602M (Q4 FY2026 4C). |
Liquidity of the stock | Average daily volume of about 81k shares (Yahoo), roughly A$1.8k per day, which is very illiquid |
Index membership | None; not held by ETFs |
Equity raising history (recent) | A$7.0M at A$0.022 (FY2026); A$4.76M at about A$0.035 (FY2025); about A$4.0M in 2023 |
Analyst Conclusions
Management guidance
No numerical revenue or earnings guidance has been given. Qualitative priorities are TPR feedlot adoption, North American access and diversification. The single quantified aspiration is TPR use of up to 160,000 head in CY2027, subject to trial success and customer scale-up. The going-concern forecast shows sufficient cash through 31 March 2028.
Consensus: none.
Bull case
-
The trial converts into the first meaningful recurring revenue. Suppose the 10,600-head Mort & Co / MLA trial (data January 2027) replicates the Charles Sturt University result of about A$57 per carcass. Then Mort & Co orders begin under an already-executed supply agreement, and Ravensworth's minimum of 360,000 doses adds a floor. Even a fraction of the 160,000-head CY2027 scenario would represent a step-change from FY2026 animal-probiotic revenue of A$1.12M.
-
North America re-rates the addressable market. US approval (expected December 2026), AAFC feedlot data and a North American distributor (targeted January 2027) could open royalty or distribution economics without Terragen building a sales force. That would be a potential licensing inflection against a roughly A$11M enterprise value.
-
Scalable gross margin and a funded runway. Gross margin is already around 59%. The FY2026 raise funds operations to March 2028, so revenue growth could narrow losses without proportionate cost growth, because fixed administration of about A$2.8M does not scale with volume.
Bear case
-
The commercial record is deteriorating, not improving. Revenue has fallen for three straight years to A$1.43M, and 1H FY2026 sales fell 26%. Each new product (TPR, Naturalift) has so far failed to offset decline elsewhere. The 160,000-head scenario rests on multiple conditions outside Terragen's control.
-
Dilution remains the business model. Accumulated losses are A$49M against A$57.9M of capital raised. The share count rose 123% in two years. Burn of about A$3.4–3.6M per year means another raise is likely before FY2028, probably at a low price given illiquidity and the 33.7% blockholder.
-
Execution and governance fragility. There have been five CFO arrangements in about 27 months, ending with a fractional outsourced CFO. The company has a single manufacturing site, roughly 25% customer concentration, and a distributor (Nutrien) building competing biologicals. Global majors with vastly greater R&D and distribution budgets compete in both of its product categories.
Key catalysts and monitorables (next 12 months)
| Expected timing | Catalyst / monitorable |
|---|---|
| By 31 Oct 2026 | Q1 FY2027 Appendix 4C: receipts trend, inventory drawdown, cash burn |
| Nov 2026 | Canine probiotic microbiome sequencing results; any partner agreement |
| 27 Nov 2026 | 2026 AGM: director elections, remuneration report vote, any option or placement-capacity resolutions |
| By 1 Dec 2026 (or 90 days after conditions met) | Ravensworth minimum order placement; dispenser installation and feedlot expansion |
| Dec 2026 | US market-access approval for TPR (Knoell estimate); AAFC study concludes; Mort & Co trial ends |
| Jan 2027 | Canadian and Mort & Co / MLA trial data release; targeted North American distribution agreement |
| Late Jan 2027 | Q2 FY2027 4C: first Ravensworth deliveries |
| Feb 2027 | 1H FY2027 results: evidence of revenue inflection |
| 2027 season | FAR / COGGO winter-crop results; Nutrien TPR sell-through; Coolum lease renewal (the right-of-use asset is nearly fully amortised) |
Analyst verdict
Terragen enters FY2027 at a binary juncture. On one side is a credible, increasingly independent body of evidence:
-
a Charles Sturt University feeding trial showing roughly A$57 of extra value per carcass;
-
an independent +12% maize silage yield result for Great Land Plus;
-
a 10,600-head commercial trial co-funded by Meat & Livestock Australia's Donor Company and Mort & Co to the tune of up to A$2.8M; and
-
a Canadian government-led feedlot study, with US market access expected in December 2026.
Few micro-caps can point to this degree of third-party scrutiny. The balance sheet, at A$7.25M cash with negligible debt, buys time.
On the other side, the operating record is poor. Revenue has fallen from A$3.28M in FY2023 to A$1.43M in FY2026. The cost base of about A$6M is roughly four times revenue, losses have held at A$3.0–3.75M for four years, and every earlier commercial thesis has underdelivered: international Mylo after the 2019 IPO, the Mylo-to-TPR transition, and feedlot adoption. Repeated CFO turnover and heavy reliance on one anchor shareholder add governance and funding fragility. The 160,000-head CY2027 figure is an upside scenario, not guidance.
Our assessment is that the equity is effectively a real option on two near-term readouts: the Mort & Co / MLA trial data and a North American distribution agreement, both targeted for around January 2027. At an enterprise value of roughly A$11M, which is near the value of the cumulative non-dilutive validation now under way, the market is pricing a high probability of failure. Positive data and a signed distributor would likely trigger a re-rating and a better-priced raise. A null or ambiguous trial result would leave the company with a shrinking revenue base and a 2027–28 funding requirement, likely at dilutive terms.
Stance: speculative / event-driven. Position sizing should be keyed to the January 2027 data window rather than to the current fundamentals.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Tenure | Background and education | Other listed directorships (past 3 years) | Shares | Options |
|---|---|---|---|---|---|---|
Dr Michele Allan AO | Non-Executive Chair (since 6 Feb 2026) | — | BAppSc (UTS), MMgt (Technology) (Melbourne), DBA (RMIT), MCommLaw (Deakin), FAICD. Officer of the Order of Australia (Jan 2023). Chair of SmartSat CRC, Wine Australia, Trusted Autonomous Systems, Charles Sturt University and Twenty Degrees; NED of MJ Chickens; interim chair of the AgValue CRC bid. | Nil | Nil | 3,500,000 |
Michael (Mike) Barry | Non-Executive Director (Chair 30 Jun 2023 – 6 Feb 2026) | Since Jun 2023 or earlier | BBus (QUT), MBA (UQ). About 10 years in senior roles at Boral; CEO of MSF Sugar for 13 years to 2020. | Entyr Limited | 1,428,572 | 5,000,000 |
Scobie Ward | Non-Executive Director (waives fees) | Since about Sep 2023 | Started at Indosuez Asia Investment Services (1989); co-founded Lloyd George Management (1992) and Ward Ferry Management (2000, chair to 2021); pre-IPO investor | Nil | 277,077,542 (indirect) | Nil |
Andrew Guthrie | Non-Executive Director; Audit and Risk Committee Chair | Since 8 Jul 2024 | BAgrSc (Hons) (La Trobe), GAICD. 32 years at Syngenta, including Regional Director Asia Pacific and head of Europe, Africa and Middle East. Board of Cotton Seed Distributors. | Bio-Gene Technology Ltd | 285,715 (indirect) | 3,500,000 |
Paul Whimp | Non-Executive Director | Since 8 May 2026 | BBus (Acc), CA ANZ, GradDipFinPlan; director of Harris Black (accounting / advisory); former Brentnalls National chair | Carawine Resources Ltd | Nil | Nil |
Richard Norton | Managing Director and CEO | CEO since 2023/2024 (sources conflict) | MBA (Monash), GAICD. Former MD of Meat & Livestock Australia (2014–2018); former MD of Landmark Operations; GM Retail at Elders; earlier roles at Wesfarmers Dalgety, Toll, Woolworths and Coca-Cola Amatil. Past boards include AuctionsPlus (Chair), Integrated Traceability Solutions (Chair), Agrium Asia Pacific and AWB. Also Food Agility CRC CEO/MD (2021 – 30 Jun 2026, per Food Agility). | Nil | 571,429 (indirect) | 10,000,000 |
Executive Leadership Team
| Name | Title | Tenure | Background |
|---|---|---|---|
Richard Norton | MD and CEO | See above | See above |
Dr Jocelyn (Joss) West | Chief Operating Officer | Since 27 Mar 2023 | Veterinarian (BVetBiol/BVSc, Charles Sturt), MBA (Griffith), GAICD. 12 years in mixed and production-animal practice; Clinical Lead at National Vet Care (2018). Holds 516,566 shares and 7.5M options. |
Rebecca White | CFO (fractional, via Traverse Accountants) | Since 7 Oct 2026 | Also CFO and Executive Director of Tinybeans Group (ASX:TNY); former CEO and Executive Director of Revasum (ASX:RVS) |
Roger McPherson | Joint Company Secretary (CFO 11 Aug 2025 – 7 Jul 2026) | Since 11 Aug 2025 | 30+ years in finance; 20+ years in biotech, agtech and pharma; BBus (Curtin), CPA, GAICD. Paid A$1,500/day for 1–2 days per week. |
Maree Crawford | Manager, Innovation & Adoption | Appointed June quarter 2026 | Background in commercialising seeds, fertiliser and inputs |
Dr Karen Jury | Head of R&D | — | — |
Dr Paul Scott | Head of Soil Health Product Development | — | — |
Adam Davies | Head of Sales and Marketing | — | — |
Andrew Wollen | Head of New Product Applications Development | — | — |
“—” = not publicly disclosed.
Directors' Remuneration
| Name | Cash salary / fees | Super | Leave | Share-based | Bonus / other | Total | % performance-based |
|---|---|---|---|---|---|---|---|
Dr Michele Allan AO | 62,143 | 7,457 | — | 34,058 | — | 103,658 | 0% |
Michael Barry | 66,429 | 7,971 | — | 48,655 | — | 123,055 | 0% |
Scobie Ward | — | — | — | — | — | 0 (fees waived) | 0% |
Andrew Guthrie | 53,571 | 6,429 | — | 34,058 | — | 94,058 | 0% |
Paul Whimp (from 8 May 2026) | 7,866 | 944 | — | — | — | 8,810 | 0% |
Richard Norton (MD and CEO) | 260,719 | 43,286 | 14,360 | 97,310 | 100,000 | 515,675 | 19.4% |
Jocelyn West (COO) | 198,146 | 23,778 | (8,468) | 71,785 | — | 285,241 | 0% |
Roger McPherson (CFO, consultant) | 112,500 | — | — | — | — | 112,500 | 0% |
Matthew Whyte (to 27 Aug 2025) | 50,698 | 5,920 | — | — | — | 56,618 | 0% |
Total KMP | 812,072 | 95,785 | 5,892 | 285,866 | 100,000 | 1,299,615 | 7.7% |
Major Shareholders
| Holder | Shares | % of 823.2M | Source |
|---|---|---|---|
Scobie Ward (indirect, associated entities) | 277,077,542 | 33.7% | FY2026 Annual Report |
Other directors and KMP combined | 2,802,282 | 0.3% | FY2026 Annual Report |
Free float | — | about 29% (MarketScreener estimate) | Implies other large blockholders exist beyond Ward |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Type | Relative positioning |
|---|---|---|---|
Ruminant probiotics / DFMs | Novonesis (formerly Novozymes and Chr. Hansen) | Global listed biosolutions major | Dominant in microbial strains and direct-fed microbials; vastly larger R&D and global distribution |
Ruminant probiotics / DFMs | Lallemand Animal Nutrition | Global private | Established yeast and bacterial probiotics for dairy and beef |
Ruminant probiotics / feed additives | DSM-Firmenich (Bovaer® methane inhibitor) | Global listed | Leader in methane-reduction feed additives; competes for the same "climate plus productivity" budget |
Feed additives | Alltech | Global private | Broad feed-additive and yeast portfolio, strong in Australia and New Zealand |
Feedlot performance additives | Elanco; Phibro Animal Health | Global listed animal health | Ionophores and antibiotic alternatives entrenched in feedlot rations |
Methane-reduction start-ups | Rumin8 (Australia), CH4 Global, FutureFeed licensees | Private | Compete on the methane narrative and for MLA-linked validation funding |
Plant biostimulants (Australia) | RLF AgTech (ASX: RLF) | Australian listed | Liquid fertilisers and biostimulants; also signed a Nutrien Australia distribution deal (Aug 2025), a direct channel overlap |
Plant biostimulants / biologicals | Bioceres / ProFarm; Biome Makers; Lallemand Plant Care | Global | Broad biological crop inputs |
Nitrogen-fixing microbes | Pivot Bio (US) | Private | Scale leader in nitrogen-fixing microbes, directly relevant to the QUT nitrogen project |
Crop inputs majors | Syngenta Biologicals, Corteva Biologicals, BASF, Bayer | Global | Acquisitive biological portfolios with channel power |
Plant biologicals (Nutrien in-house) | Nutrien (e.g., TERRAMAR bio-solution in Western Canada, 2026) | Global listed | Terragen's key Australian distributor is also developing its own biologicals, a channel-conflict risk |
Companion-animal probiotics | Purina (Nestlé) FortiFlora, Zoetis, Virbac | Global | Entrenched veterinary probiotic brands |
Competitor Detail
| Metric | Terragen (FY2026) |
|---|---|
Revenue | A$1.43M |
Revenue growth | −11.3% |
Gross margin | 59.3% |
Net margin | −262% |
R&D intensity | 85.5% of revenue |
Recent Developments
The FY2025 termination benefits of A$184k imply some restructuring in that year.



